Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease
Conditions
Interventions
Intervention1: Benzoic acid: Oral Route of Administration
30 pill size
centesimal potencies in ascending order of potency starting with 30 potency.
First dose after case taking.
repetition according t
Sponsors
Bakson Homoeopathic Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Participants with SUA levels in males more than 7.0g/dl and females with SUA levels more than 6.0g/dl Participants may or may not be present with symptoms like joint pains, stiffness etc. Participants willing to give consent
Exclusion criteria
Exclusion criteria: Participants with unstable mental or psychiatric diseases, uncontrolled or severe systemic illness, autoimmune diseases, immunocompromised diseases. Participants with joint deformities or chronic tophaceous gout (as these cases represent irreversible pathology) Participants with chronic kidney disease ( stage 3 or higher) or serum creatinine more than 1.5mg/dl Pregnant and lactating females Participants with renal complications ( SUA levels more than 13mg/dl)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare changes of pain levels in individualised group and benzoic acid group using VAS scaleTimepoint: total 16 months study enrollment period of 6 months follow up of 6 months data analysis 2 months report writing 2 months Vas scale to be used at baseline, 4 weeks upto 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare changes in symptomatology of hyperuricemia- frequency, intensity, stiffness and mobility in individualised group and benzoic acid groupTimepoint: total 16 months study enrollment period of 6 months follow up of 6 months data analysis 2 months report writing 2 months | — |
Countries
India
Contacts
Public ContactDr Akshay Mathur
Bakson Homoeopathic Medical college and Hospital
Outcome results
None listed